C809R, the mutation with the highest relP, has been reported in a patient diagnosed with myelodysplastic syndrome-derived leukemia (Lorenzo et al., 2006), highlighting its biological relevance; however, similar to all predicted V668 mutations, this residue has not yet been associated with imatinib resistance. This evidence concerns the gene REG4 and myelodysplastic syndrome.